Jump to content

Epithelial-myoepithelial carcinoma of the lung

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Hazard-Bot (talk | contribs) at 21:41, 7 March 2016 (Bot: Adding {{Research help|Med}}; please leave feedback/comments at Wikipedia talk:Research help #ResHelp). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Epithelial-myoepithelial carcinoma of the lung (EMECL) is a very rare histologic form of malignant epithelial neoplasm ("carcinoma") arising from lung tissue.[1]

Synonyms

A number of now-obsolete terms have been used to describe EMECL in past literature,[1] including adenomyoepithelioma,[2] myoepithelioma, epithelial-myoepithelial tumor, epimyoepithelial carcinoma, and malignant mixed tumor containing epithelial and myoepithelial cells.[1]

Classification

Lung cancer is an extremely heterogeneous family of malignant neoplasms,[3] with well over 50 different histological variants recognized under the 4th revision of the World Health Organization (WHO) typing system ("WHO-2004"),[1] currently the most widely used lung cancer classification scheme. Because these variants have differing genetic, biological, and clinical properties, including response to treatment, correct classification of lung cancer cases are necessary to assure that lung cancer patients receive optimum management.[1][4][5]

The WHO-2004 scheme groups lung carcinomas into 8 major types:[1]

EMECL is considered a subtype of salivary gland-like carcinoma, tumors so named because their histological appearance and characteristics closely resemble malignant neoplasms arising in the major and minor salivary glands.

Incidence

EMECL is extremely rare, with only a handful of cases reported in the literature.[6]

In the lung, two salivary gland-like carcinomas, mucoepidermoid carcinoma and adenoid cystic carcinoma, while extremely uncommon, occur far more often than does EMECL.[1][7]

Histogenesis

Genetics

The epithelial component in EMECL's typically strongly express cytokeratins, but are negative for actin and S-100 protein, while the myoepithelial component is stains strongly for actin and S-100 protein, and only focally weakly for cytokeratins.[8]

Diagnosis

Microscopically, EMECL features bi-layered glandular or ductular structures consisting of inner cuboidal cells and outer multipolar cells.[9]

The histologic appearance of these tumors varied, but all shared the common feature of a biphasic proliferation of epithelial (strong cytokeratin-positive; actin and S-100-negative) and myoepithelial (strong actin and S-100 and focal weak cytokeratin-positive) cells with formation of bilayered ductlike structures. The focal resemblance to other salivary gland-type tumors may cause diagnostic difficulties, particularly in small endobronchial biopsies. Although little is known about their biologic potential due to limited follow-up data, these tumors when in the lung clearly have the capacity to infiltrate and metastasize and therefore should be designated as epithelial-myoepithelial carcinoma. At present, it appears that treatment by complete surgical resection with negative margins alone is appropriate and adequate.[8]

Staging

EMECL is staged in the same manner as other non-small cell lung carcinomas, based on the TNM (Tumor-Node-Metastasis) staging system.[10]

Treatment

Complete radical surgical resection is the treatment of choice for EMECL, and in most cases, results in long-term survival or cure.[11][12]

Prognosis and Survival

The prognosis of EMECL is relatively good, and considerably better than most other forms of NSCLC. The skull and dura are possible sites for metastasis from pulmonary EMC. The MIB-1 index is a predictive marker of malignant potential.

References

Template:Research help

  1. ^ a b c d e f g Travis, William D; Brambilla, Elisabeth; Muller-Hermelink, H Konrad; Harris, Curtis C, eds. (2004). Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart (PDF). World Health Organization Classification of Tumours. Lyon: IARC Press. ISBN 92 832 2418 3. Retrieved 27 March 2010.
  2. ^ Tsuji N, Tateishi R, Ishiguro S, Terao T, Higashiyama M; Tateishi; Ishiguro; Terao; Higashiyama (August 1995). "Adenomyoepithelioma of the lung". Am. J. Surg. Pathol. 19 (8): 956–62. doi:10.1097/00000478-199508000-00012. PMID 7611543.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  3. ^ Roggli VL, Vollmer RT, Greenberg SD, McGavran MH, Spjut HJ, Yesner R; Vollmer; Greenberg; McGavran; Spjut; Yesner (June 1985). "Lung cancer heterogeneity: a blinded and randomized study of 100 consecutive cases". Hum. Pathol. 16 (6): 569–79. doi:10.1016/S0046-8177(85)80106-4. PMID 2987102.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  4. ^ Rossi G, Marchioni A, Sartori1 G, Longo L, Piccinini S, Cavazza A (2007). "Histotype in non-small cell lung cancer therapy and staging: The emerging role of an old and underrated factor". Curr Resp Med Rev. 3: 69–77. doi:10.2174/157339807779941820. {{cite journal}}: Unknown parameter |doi_brokendate= ignored (|doi-broken-date= suggested) (help)CS1 maint: multiple names: authors list (link) CS1 maint: numeric names: authors list (link)
  5. ^ Vincent MD (August 2009). "Optimizing the management of advanced non-small-cell lung cancer: a personal view". Curr Oncol. 16 (4): 9–21. doi:10.3747/co.v16i4.465. PMC 2722061. PMID 19672420.
  6. ^ Doganay L, Bilgi S, Ozdil A, Yoruk Y, Altaner S, Kutlu K; Bilgi; Ozdil; Yoruk; Altaner; Kutlu (April 2003). "Epithelial-myoepithelial carcinoma of the lung. A case report and review of the literature". Arch. Pathol. Lab. Med. 127 (4): e177–80. doi:10.1043/0003-9985(2003)127<e177:ECOTL>2.0.CO;2. PMID 12683896. {{cite journal}}: Unknown parameter |doi_brokendate= ignored (|doi-broken-date= suggested) (help)CS1 maint: multiple names: authors list (link)
  7. ^ Travis WD, Travis LB, Devesa SS; Travis; Devesa (January 1995). "Lung cancer". Cancer. 75 (1 Suppl): 191–202. doi:10.1002/1097-0142(19950101)75:1+<191::AID-CNCR2820751307>3.0.CO;2-Y. PMID 8000996.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  8. ^ a b Nguyen CV, Suster S, Moran CA; Suster; Moran (March 2009). "Pulmonary epithelial-myoepithelial carcinoma: a clinicopathologic and immunohistochemical study of 5 cases". Hum. Pathol. 40 (3): 366–73. doi:10.1016/j.humpath.2008.08.009. PMID 18973918.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  9. ^ Okudela K; Yazawa T; Tajiri M (February 2010). "A case of epithelial-myoepithelial carcinoma of the bronchus - a review of reported cases and a comparison with other salivary gland-type carcinomas of the bronchus". Pathol. Res. Pract. 206 (2): 121–9. doi:10.1016/j.prp.2009.03.003. PMID 19369010. {{cite journal}}: Cite has empty unknown parameter: |author-separator= (help); Unknown parameter |displayauthors= ignored (|display-authors= suggested) (help)
  10. ^ Rami-Porta R, Crowley JJ, Goldstraw P; Crowley; Goldstraw (February 2009). "The revised TNM staging system for lung cancer". Ann Thorac Cardiovasc Surg. 15 (1): 4–9. PMID 19262443.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  11. ^ Muro M; Yoshioka T; Idani H (March 2010). "肺に発生した上皮-筋上皮癌". Kyobu Geka (in Japanese). 63 (3): 220–3. PMID 20214352. {{cite journal}}: Cite has empty unknown parameter: |author-separator= (help); Unknown parameter |displayauthors= ignored (|display-authors= suggested) (help); Unknown parameter |trans_title= ignored (|trans-title= suggested) (help)
  12. ^ Nishihara, Masamitsu; Takeda, Naoya; Tatsumi, Shoutarou; Kidoguchi, Keiji; Hayashi, Shigeto; Sasayama, Takashi; Kohmura, Eiji; Hashimoto, Kimio (2011). "Skull Metastasis as Initial Manifestation of Pulmonary Epithelial-Myoepithelial Carcinoma: A Case Report of an Unusual Case". Case Reports in Oncological Medicine. 2011: 1. doi:10.1155/2011/610383.{{cite journal}}: CS1 maint: unflagged free DOI (link)
Retrieved from "https://en.wikipedia.org/w/index.php?title=Epithelial-myoepithelial_carcinoma_of_the_lung&oldid=708836503"